Radiolabeled peptides in the diagnosis and therapy of oncological diseases
- 4 September 2002
- journal article
- review article
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 57 (5) , 749-763
- https://doi.org/10.1016/s0969-8043(02)00192-6
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Receptor-mediated radiotherapy with 90Y-DOTATOC: Towards the right doseNuclear Medicine Communications, 2000
- 90Y-DOTA-lanreotide: Dosimentry and toxicityNuclear Medicine Communications, 2000
- Early experience with Y-90 Lanreotide therapyNuclear Medicine Communications, 2000
- DOTA-Lanreotide: A Novel Somatostatin Analog for Tumor Diagnosis and TherapyEndocrinology, 1999
- Technetium‐99m labeled epidermal growth factor‐tumor imaging in miceChemical Biology & Drug Design, 1997
- DOTATOC: a powerful new tool for receptor-mediated radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997
- Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasmsNuclear Medicine and Biology, 1996
- Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphyEuropean Journal Of Cancer, 1995
- Somatostatin receptor expression in lung cancerEuropean Journal Of Cancer, 1994
- High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor‐host interaction?International Journal of Cancer, 1994